99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexMale
Age18+
SponsorFirst Affiliated Hospital of Chongqing Medical University
About this trial
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
At least 18 years of age.
Signed informed consent.
Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Disqualifiers
Patients with PSMA negative expression.
Patients with pregnancy.
The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components.
Trial design
Design model
Single group
Treatments tested in this trial
99mTc-QULIC-5-P1
DrugEach subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: 99mTc-QULIC-5-P1Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Diagnostic efficacy
The sensitivity, specificity, and accuracy of 99mTc-QULIC-5-P1 SPECT
Time frame
15 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov